

KEY:	Please note the program takes place in CET - Central European Time Barcelona					
PRE CONFERENCE SYMPOSIUM	SPONSORED SYMPOSIUM	SYMPOSIUM	PLENARY LECTURE	FORUM	OTHER EVENT	
<b>Tuesday, March 15, 2022</b>						
	Onsite - PLENARY 115-117	Onsite - 112	<b>Please note that On-Demand Sessions are listed at the end of this program.</b>			
08:30 - 17:00	PRE CONFERENCE SYMPOSIUM 1 REGISTRATION REQUIRED	PRE CONFERENCE SYMPOSIUM 2 REGISTRATION REQUIRED				
<b>Wednesday, March 16, 2022</b>						
	On-Demand Oral					
07:00 - 08:30	SEE BREAKDOWN BELOW					
	Onsite - PLENARY 115-117	Onsite - 112	Onsite - 114	Onsite - 113	Onsite-131-132	Onsite-133-134
08:30 - 10:30	FLUID BIOMARKERS 1	TAU-TARGETED TREATMENT STRATEGIES	INDIVIDUAL CELL TYPES< ORGANOIDs AND ANIMAL MODELS IN AD, PD (1) MECHANISTIC & TRANSLATIONAL ASPECTS	GENETICS OF NEURODEGENERATION 1	SINGLE-CELL GENOMICS STEM CELLS 2	NEUROPATHOLOGY IN AD, LBD AND OTHER DEMENTIA & TRANSCRANIAL PULSE STIMULATION
10:30 - 11:00	COFFEE BREAK:PRODUCT THEATRE, EXHIBITION AND POSTERS					
11:00 - 11:30	OPENING CEREMONY AND AWARDS					
11:30 - 12:00	PLENARY LECTURE 1: REGULATION OF SYNAPTIC FUNCTION BY ALZHEIMER'S ASSOCIATED GENES					
12:00 - 12:30	PLENARY LECTURE 2: FLUID AND PET IMAGING BIOMARKERS FOR ALZHEIMER'S AND PARKINSON'S DISEASES					
12:30 - 13:00	PLENARY LECTURE 3: KEY MILESTONES IN ALZHEIMER'S DISEASE					
13:00 - 14:00	BREAK: EXHIBITION AND POSTERS					
14:00 - 15:45	INDUSTRY SYMPOSIUM (NONE CME/CPD CREDIT)					
15:45 - 16:15	COFFEE BREAK: EXHIBITION AND POSTERS					
16:15 - 17:15	INDUSTRY SYMPOSIUM (NONE CME/CPD CREDIT)	PATHOLOGICAL CELLULAR NICHES, ABETA STRUCTURE, AMYLOID PLAQUES AND NEURODEGENERATION	GENETICS OF NEURODEGENERATION 2	MICROGLIA, TREM2, NEUROINFLAMMATION	AD ANIMAL MODELS & TRANSLATIONAL ASPECTS	TDP43- AND C9ORF72-RELATED DISEASES 1
17:30 - 18:15	ANTI-TAU APPROACHES IN CLINICAL TRIALS (17:30 - 18:30)					
18:15 - 19:15	BLOOD-BASED BIOMARKERS COMPARISON TO FLUID-BASED BIOMARKERS, IMAGING, AND ASSESSMENT OF DIAGNOSTIC & TREATMENT EFFECTS TREATMENT EFFECT: HOW TO MEASURE MINIMAL CLINICAL EFFICACY? (18:30- 19:30)					
19:40 - 20:20	<b>ONSITE WELCOME RECEPTION IN THE EXHIBITION</b>					

Thursday, March 17, 2022

	On-Demand Oral					
07:00 - 08:30	SEE BREAKDOWN BELOW					
	Onsite - PLENARY 115-117	Onsite - 112	Onsite - 114	Onsite - 113	Onsite-131-132	Onsite-133-134
08:30 - 09:00	PLENARY LECTURE 4: DISEASE MODIFICATION IN PD: WHAT ARE THE PROMISING TARGETS?					
09:00 - 09:10	BREAK					
09:10 - 11:10	INDUSTRY SYMPOSIUM (NONE CME/CPD CREDIT)	CLINICAL TRIALS DESIGN, HETEROGENEITY OF SYMPTOMS, RESPONSE TO TREATMENT, DIAGNOSTICS, IMAGING AND BIOMARKERS IN AD, FTLD	CHOLINERGIC MECHANISMS IN AD AND PD	SINGLE-CELL GENOMICS STEM CELLS 3	LIPIDS, FATTY ACIDS	ADVANCES IN AD, PD AND LBD DRUG DEVELOPMENT
11:10 - 11:40	COFFEE BREAK:PRODUCT THEATRE, EXHIBITION AND POSTERS					
11:40 - 13:25	INDUSTRY SYMPOSIUM (NONE CME/CPD CREDIT)					
13:25 - 14:45	BREAK: EXHIBITION AND POSTERS					
14:45 - 16:45	INDUSTRY SYMPOSIUM (NONE CME/CPD CREDIT) (14:45 - 15:45)	APOE: MECHANISMS AND TREATMENT STRATEGIES	ALPHA-SYNUCLEIN AND DISEASE MECHANISMS	DISEASE MECHANISMS, INFLAMMATION. MICROGLIA, ASTROCYTES, AMYLOIDS	AD: DISEASE MECHANISMS, PATHOPHYSIOLOGY: SYNAPTIC INTEGRITY & PLASTICITY	NEUROPATHOLOGY IN AD, LBD AND OTHER DEMENTIA 2
	TRANSLATIONAL DRUG DISCOVERY IN PD/ LBD PHASE I-III - RECENT UPDATES (15:50 - 16:50)					
16:45 - 17:15	COFFEE BREAK:EXHIBITION AND POSTERS					
17:15 - 19:15	INDUSTRY SYMPOSIUM (NONE CME/CPD CREDIT)	CONGOPHILIC AMYLOID ANGIOPATHY (CAA), VASCULAR DEMENTIA, VASCULAR DAMAGE IN DEMENTIA, BLOOD-BRAIN BARRIER, ARIA	APOE MECHANISMS AND TREATMENT STRATEGIES	MRI 1	RISK PATHWAYS, EEG, DIGNOSTICS, PATIENT CARE AND SUPPORT	MITOCHONDRIAL DEFECTS IN AD, PD

**Friday, March 18, 2022**

	<b>On-Demand Oral</b>					
07:00 - 08:30	<b>SEE BREAKDOWN BELOW</b>					
	Onsite - PLENARY 115-117	Onsite - 112	Onsite - 114	Onsite - 113	Onsite-131-132	Onsite-133-134
08:30 - 09:00	<b>PLENARY LECTURE 5: TAU AND DIVERSITY OF DRIVERS IN ALZHEIMER DISEASE</b>					
09:00 - 09:10	BREAK					
09:10 - 11:10	TRANSLATIONAL TREATMENT STRATEGIES AND NEW TARGETS IN AD	ALPHA-SYNUCLEIN- DISEASE MECHANISMS, DETECTION & THERAPEUTIC RELEVANCE	FTD, ALS; C9ORF72, TDP-43 AND PROGRAMULIN	INDUSTRY SYMPOSIUM (NONE CME/CPD CREDIT)	FLUID BIOMARKERS 2	RISK PATHWAYS, INSULIN, PSYCHOSOCIAL AND PSYCHIATRIC SYMPTOMS IN NEURODEGENERATIVE DISEASES
11:10 - 11:40	COFFEE BREAK:PRODUCT THEATRE, EXHIBITION AND POSTERS					
11:40 - 13:25	<b>INDUSTRY SYMPOSIUM (NONE CME/CPD CREDIT)</b>					
13:25 - 14:45	BREAK: EXHIBITION AND POSTERS					
14:45 - 16:45	INDUSTRY SYMPOSIUM (NONE CME/CPD CREDIT) (14:45 - 15:45)	ABETA TARGETING THERAPIES IN AD 1	TAU PROPAGATION AND CELLULAR INTERACTIONS 1	FLUID BIOMARKERS 3	DISEASE MECHANISMS, INFLAMMATION. MICROGLIA, ASTROCYTES, IMMUNE MODULATION, MEMBRANE TRAFFICKING	AD, PD, LBD: MACHINE LEARNING, DEEP LEARNING, EEG, DIAGNOSIS. & CLINICAL TRIALS
	PHASE I-III IN AD: MORE THAN TWO TARGETS? (15:50 - 16:50)					
16:45 - 17:15	COFFEE BREAK:EXHIBITION AND POSTERS					
17:15 - 19:15	ABETA TARGETING THERAPIES IN AD 2	MRI 2	GLUCOCEREBROSIDASE, LRRK2-PD AND ALPHA-SYNUCLEIN	ALPHA-SYNUCLEIN, PD ANIMAL MODELS, MECHANISTIC ASPECTS AND THERAPEUTIC STRATEGIES	VASCULAR FACTORS	AD, PD, MSA MECHANISMS, DIAGNOSIS, BIOMARKERS, IMAGING & TRASLATIONAL DRUG DEVELOPMENT

Saturday, March 19, 2022

	<b>On-Demand Oral</b>					
07:00 - 08:30	<b>SEE BREAKDOWN BELOW</b>					
	Onsite - PLENARY 115-117					
	Onsite - 112	Onsite - 114	Onsite - 113	Onsite-131-132	Onsite-133-134	
08:30 - 09:00	<b>PLENARY LECTURE 6: MICROGLIAL TAM RECEPTORS IN ALZHEIMER'S DISEASE</b>					
09:00 - 09:10	BREAK					
09:10 - 11:10	INDUSTRY SYMPOSIUM (NONE CME/CPD CREDIT)	AD DIAGNOSIS & CLINICAL TRIALS & ADVANCES IN DRUG DEVELOPMENT 4	TAU PROPAGATION AND CELLULAR INTERACTIONS 2	AD, LBD DIAGNOSIS, IMAGING & CLINICAL TRIALS	FLUID BIOMARKERS 4	SYNUCLEINOPATHIES, PRIONS DISEASE, MECHANISMS & BIOMARKERS, DIAGNOSTICS
11:10 - 11:40	COFFEE BREAK:EXHIBITION AND POSTERS					
11:40 - 13:25	INDUSTRY SYMPOSIUM (NONE CME/CPD CREDIT)					
13:25 - 14:45	BREAK: EXHIBITION AND POSTERS					
14:45 - 16:45	INDUSTRY SYMPOSIUM (NONE CME/CPD CREDIT) (14:45 - 15:45) <b>AMYLOID-REMOVING THERAPIES: THE BEGINNING OF THE END OR THE END OF THE BEGINNING?</b> (15:50 - 16:50)	ADVANCES IN PD AND LBD DRUG DEVELOPMENT 1	FLUID BIOMARKERS 5	TAUPATHIES: MECHANISMS & TREATMENT STRATEGIES 2	EEG, SLEEP AND ELECTROPHYSIOLOGY	DIAGNOSTIC ACCURACY, IMAGING AND FLUID BIOMARKERS IN AD, FTD, PD, LBD
16:45 - 17:15	COFFEE BREAK:EXHIBITION AND POSTERS					
17:15 - 19:15	DIAGNOSTIC ACCURACY, IMAGING AND FLUID BIOMARKERS IN AD, PD, LBD	BACE-1, BACE-2, PRESENILIN, GAMMA-SECRETASE., TACE AND APP PROCESSING & Abeta TRUNCATION, TOXICITY	COINCIDENT NEURODEGENERATIVE DISEASE, AMYLOID, TAU , TDP-43 PATHOLOGY	AD HETEROGEINITY , DIAGNOSTIC AIDS AND CLINICAL TRIALS	AD, FTD, LBD DIAGNOSIS. EEG & CLINICAL TRIALS & ADVANCES IN DRUG DEVELOPMENT	GENETICS OF NEURODEGENERATION 2

Sunday, March 20, 2022				
	On-Demand Oral			
07:00 - 08:30	SEE BREAKDOWN BELOW			
	Onsite - PLENARY 115-117	Onsite - 112	Onsite - 114	Onsite - 113
08:30 - 09:00	PLENARY LECTURE 7: STOMPING OUT THE SPARK: TARGETING PYROGLU3 AMYLOID-BETA FOR THE TREATMENT OF ALZHEIMER'S DISEASE			
09:00 - 09:05	BREAK			
09:05 - 11:05	COVID-19 IMPACT ON NEURODEGENERATIVE DISEASES	RESILIENCE AND VULNERABILITY FACTORS, RISK ASSESSMENT, PREVENTION, CLINICAL TRIALS	BRAIN GUT INTERACTIONS MICROBIOME	ABETA AND OTHER TARGETING THERAPIES IN AD
11:05 - 11:35	COFFEE BREAK			
11:35 - 13:35	TRANSLATIONAL DRUG DISCOVERY: THE VALUE OF ANIMAL MODELS, ORGANIDS, DIGITAL, AI (11:35 - 12:35)	ADVANCES IN PD AND LBD DRUG DEVELOPMENT 2	SEX AND GENDER IN NEURODEGENERATIVE DISEASES	WHITE MATTER (WM) ABNORMALITIES
	IMPACT OF COVID-19 ON NEURODEGENERATIVE DISEASES (12:40 - 13:40)			
13:40 - 14:00	CLOSING CEREMONY			

On-Demand Sessions - Available from the first day of the congress in the Online Gallery

On-Demand Sessions - Available from the first day of the congress in the Online Gallery						
	<b>Wednesday, March 16, 2022</b>					
	SINGLE-CELL GENOMICS STEM CELLS 1					
	NEUROPATHOLOGY IN AD, LBD AND OTHER DEMENTIA 1					
	AD DIAGNOSIS & CLINICAL TRIALS & ADVANCES IN DRUG DEVELOPMENT 1					
	AD DIAGNOSIS & CLINICAL TRIALS & ADVANCES IN DRUG DEVELOPMENT 2					
	AD DIAGNOSIS & CLINICAL TRIALS & ADVANCES IN DRUG DEVELOPMENT 3					
	NEUROPATHOLOGY VASCULAR SYSTEM, INFLAMMATION, MITOCHONDRIA, DIAGNOSTICS, AD, PD, PSP AND RELATED DISEASES					
	<b>Thursday, March 17, 2022</b>					
	AMYLOIDS, TAU ALPHA-SYNUCLEIN, PRIONS. PROTEIN MISFOLDING; DISEASE MECHANISMS & DETECTION 2					
	AD: DIAGNOSIS, CLINICAL TRIALS & ADVANCES IN TRANSLATIONAL DRUG DEVELOPMENT					
	AD ANIMAL MODELS AND MECHANISTIC & TRANSLATIONAL ASPECTS 1					
	AMYLOIDS, TAU ALPHA-SYNUCLEIN, PRIONS. PROTEIN MISFOLDING; DISEASE MECHANISMS & DETECTION 1					
	AD IMAGING, BIOMARKERS, DIAGNOSTICS, CLINICAL TRIAL DESIGNS					
	PD, LBD DIAGNOSIS & CLINICAL TRIALS & ADVANCES IN TRANSLATIONAL DRUG DEVELOPMENT					
	<b>Friday, March 18, 2022</b>					
	APP, APLP, AMYLOIDS, BACE-1, PRESENLIN: CELL, MOLECULAR, METABOLOMICS, TRANSCRIPTOMICS AND SYSTEMS BIOLOGY					
	PD, LBD MECHANISMS, DIAGNOSIS, BIOMARKERS, IMAGING					
	GENETICS OF NEURODEGENERATION 3					
	CHARACTERIZATION OF DISEASE, PATIENT CARE AND SUPPORT					
	INSULIN SIGNALING, RISK PATHWAYS, CHARACTERIZATION OF DISEASE					
	DISEASE MECHANISMS, INFLAMMATION. MICROGLIA, APOE ASTROCYTES, AMYLOIDS, LIPIDS, FATTY ACIDS 1					
	<b>Saturday, March 19, 2022</b>					
	TAUPATHIES: MECHANISMS & TREATMENT STRATEGIES 1					
	AD DIAGNOSIS, IMAGING & TRANSLATIONAL DRUG DEVELOPMENT					
	DISEASE MECHANISMS, INFLAMMATION. MICROGLIA, APOE ASTROCYTES, AMYLOIDS, LIPIDS, FATTY ACIDS 2					
	PD, MSA ANIMAL MODELS, MECHANISTIC ASPECTS AND THERAPEUTIC STRATEGIES					
	TAU, PROTEIN MISFOLDING; ASTROCYTES, DISEASE MECHANISMS & DETECTION					
	TDP43- AND C9ORF72-RELATED DISEASES 2					
	<b>Sunday, March 20, 2022</b>					
	DIAGNOSTIC ACCURACY, BIOMARKERS IN AD, CAA, PD, LBD					
	MOLECULAR MECHANISMS IN PROTEINOPATHY, TAUOPATHIES AND SYNUCLEINOPATHIES					
	AD ANIMAL MODELS AND MECHANISTIC & TRANSLATIONAL ASPECTS 2					
	AD ANIMAL MODELS AND MECHANISTIC & TRANSLATIONAL ASPECTS 3					
	COVID-19 AND OTHER VIRUSES: IMPACT ON NEURODEGENERATIVE DISEASES					
	PD, MSA DISEASE MECHANISMS, DIAGNOSIS BIOMARKERS, MICROBIOME					